v3.20.1

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Operating Expenses
General and administrative	$ 3,514	$ 2,055
Professional	34,324	34,245
Stock based compensation	421,912
Total Operating Expenses	459,750	36,300
Net loss from operations	(459,750)	(36,300)
Other expense
Interest expense	(166,296)	(24,955)
Total other expense	(166,296)	(24,955)
Net loss before taxes	(626,046)	(61,255)
Provision for income taxes
Loss from Continuing Operations	(626,046)	(61,255)
Discontinued operations
Loss from discontinued operations		(8,250)
Loss on disposal of assets and liabilities		(4,033)
Loss from Discontinued Operations, Net of Tax Benefits		(12,283)
Net loss	$ (626,046)	$ (73,538)
Net Loss Per Common Share - Basic and Diluted	$ (0.10)	$ (0.30)
Weighted Average Common Shares Outstanding	6,371,283	242,516

Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

BIOSCIENCE NEUTRACEUTICALS, INC. 10-K